Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles

Gioia, Sante Di; Trapani, Adriana; Mandracchia, Delia; Giglio, Elvira De; Cometa, Stefania; Mangini, Vincenzo; Arnesano, Fabio; Belgiovine, Giuliana; Castellani, Stefano; Pace, Lorenzo; Lavecchia, Michele Angelo; Trapani, Giuseppe; Conese, Massimo; Puglisi, Giovanni; Cassano, Tommaso

doi:10.1016/j.ejpb.2015.05.019

Cited by 90 publications

(53 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…L-DOPA loaded CD-based nanosponges have been generated by Trotta et al (2016 [80]) using molecular imprinting with encouraging results for the further storage and controlled delivery of L-DOPA in PD patients. CDs are also used as drug carriers to promote the delivery of dopamine to the brain by nasal route, in particular SBE7-β-CD [87] or maleic acid solution containing HPβCD [84] have shown promising results.…”

Section: Parkinson's Disease (Pd)mentioning

confidence: 99%

See 1 more Smart Citation

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

et al. 2016

View full text Add to dashboard Cite

Cardiovascular diseases, like atherosclerosis, and neurodegenerative diseases affecting the central nervous system (CNS) are closely linked to alterations of cholesterol metabolism. Therefore, innovative pharmacological approaches aiming at counteracting cholesterol imbalance display promising therapeutic potential. However, these approaches need to take into account the existence of biological barriers such as intestinal and blood-brain barriers which participate in the organ homeostasis and are major defense systems against xenobiotics. Interest in cyclodextrins (CDs) as medicinal agents has increased continuously based on their ability to actively extract lipids from cell membranes and to provide suitable carrier system for drug delivery. Many novel CD derivatives are constantly generated with the objective to improve CD bioavailability, biocompatibility and therapeutic outcomes. Newly designed drug formulation complexes incorporating CDs as drug carriers have demonstrated better efficiency in treating cardiovascular and neurodegenerative diseases. CD-based therapies as cholesterol-sequestrating agent have recently demonstrated promising advances with KLEPTOSE ® CRYSMEB in atherosclerosis as well as with the 2-hydroxypropyl-β-cyclodextrin (HPβCD) in clinical trials for Niemann-Pick type C disease. Based on this success, many investigations evaluating the therapeutical beneficial of CDs in Alzheimer's, Parkinson's and Huntington's diseases are currently on-going.

show abstract

Section: Parkinson's Disease (Pd)mentioning

confidence: 99%

“…Enhances drug delivery across the BBB [85], conjugated with dopamine receptor agonist methyl-β-CD Reduces α-synuclein protein aggregation [86] SBE7-β-CD Nasal delivery system for L-DOPA into the brain [87], incorporated in nanoparticles with L-DOPA Huntington's disease…”

Section: Hpβcdmentioning

confidence: 99%

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Chitosan is a natural polymer that has already proven to be a valuable building block for the formulation of NPs as it is able to deliver several drugs, including DA [15][16][17]. Furthermore, its utility in delivering drugs for treating neurological diseases has been recognized because of its ability to positively interfere in neurological processes, which occurs by chelating Cu 2+ ions that can produce hydroxyl radicals causing lipid peroxidation [18,19].…”

Section: Introductionmentioning

confidence: 99%

“…However, this leads to several undesired side-effects. Thus, to reduce the occurrence of side-effects, the delivery of DA has been attempted in various ways through nanotechnological approaches [5,15,17,20,21].…”

Section: Introductionmentioning

confidence: 99%

Neuroprotective Investigation of Chitosan Nanoparticles for Dopamine Delivery

et al. 2018

View full text Add to dashboard Cite

Featured Application: Chitosan nanoparticles are potential candidates for the delivery of various drugs, including dopamine.Abstract: Chitosan nanoparticles (CS NPs) have been widely exploited for the delivery of various types of drugs due to their biocompatibility, availability, ease of functionalization and other advantages. Nevertheless, despite their wide use, their mechanism of action is not very clear and many aspects still need to be investigated in detail, with only a few studies having studied the behavior of this polymer. We prepared CS NPs encapsulating dopamine (DA) and studied the generation of reactive oxygen species (ROS) and the antioxidant effect of the neurotransmitter in detail. Encapsulation of the drug and its subsequent sustained release significantly reduced the oxidation rate in vitro, thus potentially exerting neuroprotective effects. ROS production in SH-SY5Y cells was investigated through a H 2 O 2 assay, while a deeper study of the enzymatic activity allowed us to determine the significant contribution of both GPx and SOD enzymes in preventing oxidative stress.

show abstract

“…20,21 For another example, a sulfated polysaccharide fucoidan was reported to effectively stabilize iron oxide nanoparticles in aqueous environment. 22 Therefore, the objective of the present study was to stabilize PBNPs by sulfonate group modification and maintain their drug-loading, drug-releasing and mucoadhesion advantages (Figure 1).…”

mentioning

confidence: 99%

Sulfonate-modified phenylboronic acid-rich nanoparticles as a novel mucoadhesive drug delivery system for vaginal administration of protein therapeutics: improved stability, mucin-dependent release and effective intravaginal placement

Li¹,

Huang²,

Liu³

et al. 2016

IJN

View full text Add to dashboard Cite

Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles

Cited by 90 publications

References 60 publications

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

Neuroprotective Investigation of Chitosan Nanoparticles for Dopamine Delivery

Sulfonate-modified phenylboronic acid-rich nanoparticles as a novel mucoadhesive drug delivery system for vaginal administration of protein therapeutics: improved stability, mucin-dependent release and effective intravaginal placement

Contact Info

Product

Resources

About